general
기타
Alebund Pharmaceuticals Announces First Participant Randomized and Dosed in Global Phase IIb Multi-Regional Clinical Trial of AP306 for Hyperphosphatemia
The Laotian Times - Latest
SHANGHAI, July 21, 2026 /PRNewswire/ — Alebund Pharmaceuticals (Jiangsu) Limited (“Alebund” or the “Company”; HKEX: 09637), a renal-focused biopharmaceutical company, today announced that the first participant has been randomized and dosed in the global Phase IIb multi-regional clinical trial of AP306 in patients with hyperphosphatemia receiving maintenance hemodialysis (NCT06712654).
The trial is being conducted at […] ...
이 뉴스, 어떠셨어요?
탭 한 번으로 반응 · 로그인 불필요
관련 뉴스
관련 뉴스 제보는 로그인 후 가능합니다.
'general' 카테고리 뉴스
Registro Conavi 2026: ¿Cuál será el último día para registrarte y acceder a una Vivienda para el Bienestar?
El Informador - México
UNA sale en defensa de la institucionalidad democrática
Delfino.cr - Portada
Organizaciones piden condiciones dignas para personas Ngäbe-Buglé en cosechas de café
Delfino.cr - Portada
The Laotian Times의 다른 기사
Hong Kong Financial Services Secretary Visits Lao Bullion Bank and LIPMER
The Laotian Times - Latest
CSTS Debuts PremierX™ Globally with High-Impact FIFA World Cup Final Celebrations in New York and Hong Kong
The Laotian Times - Latest
Two Million Downloads, One Commitment: Moomoo Malaysia Partners Squash Legend Datuk Nicol David to Invest in Malaysia’s Youth
The Laotian Times - Latest